User:Mr. Ibrahem/Cerliponase alfa

Cerliponase alfa, marketed as Brineura, is a medication used to treat late infantile neuronal ceroid lipofuscinosis type 2 (CLN2). In symptomatic children over three years old it slows loss of muscle function. It is given by direct infusion into the ventricles of the brain.

Common side include fever, vomiting, headache,seizures, upper respiratory tract infection, and allergic reactions. Other side effects may include arrhythmias, meningitis, and anaphylaxis. It works by replacing the missing enzyme tripeptidyl peptidase 1 (TPP1).

Cerliponase alfa was approved for medical use in the United States and Europe in 2017. In Canada it costs about 844,000 CAD per year as of 2019. In the United States this amount costs about 710,000 USD.